<i>A novel FOXP3</i> knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products.

"Declaration of interests The authors declare no competing interests."

"We thank Dr. Neehar Bhatia (Laboratory for Cell and Gene Medicine, Stanford University School of Medicine) for the insightful advice on the clinical translation of the project. We thank the Stanford Institute for Stem Cell Biology and Regenerative Medicine FACS Core for the technical assistance. We thank Stanford Veterinary Service Center (VSC) for supporting the animal experiments. We acknowledge Stanford’s Binns Program for Cord Blood Research for providing cell products for our research. We thank Dr. Laura Passerini (San Raffaele Telethon Institute for Gene Therapy) for setting up the initial in vivo experimental protocol to test basiliximab. We gratefully acknowledge Dr. Rhonda Perriman for thoughtful feedback and revision of the manuscript. R.B., Y.S., and A.N. were supported by the 10.13039/100007557California Institute of Regenerative Medicine (CIRM) CLIN-1 grant (11591 to RB). R.B. is an Anne T. and Robert M. Bass Faculty Scholar in Pediatric Cancer and Blood Diseases, Stanford University School of Medicine."